Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 2, 2009, Pages 574-590

  Grauer, Steven M ^a   Pulito, Virginia L ^a   Navarra, Rachel L ^a   Kelly, Michele P ^a   Kelley, Cody ^a   Graf, Radka ^a   Langen, Barbara ^b   Logue, Sheree ^a   Brennan, Julie ^a   Jiang, Lixin ^a   Charych, Erik ^a   Egerland, Ute ^b   Liu, Feng ^a   Marquis, Karen L ^a   Malamas, Michael ^a   Hage, Thorsten ^b   Comery, Thomas A ^a   Brandon, Nicholas J ^a  

^a PFIZER INC   (United States)

^b Biotie Therapies GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[ 4 ( 1 METHYL PYRIDIN 4 YL 1H PYRAZOL 3 YL)PHENOXY]METHYL]QUINOLINE; AMPA RECEPTOR; APOMORPHINE; DIZOCILPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR 1; HALOPERIDOL; MP 10; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; PAPAVERINE; PHOSPHODIESTERASE 10A INHIBITOR; PHOSPHODIESTERASE INHIBITOR; QUINOLINE DERIVATIVE; ROLIPRAM; SERINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; AUDITORY RESPONSE; AVOIDANCE BEHAVIOR; CELL SURFACE; CHEMICAL ANALYSIS; CLIMBING; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEGATIVE SYNDROME; NONHUMAN; ODOR; POSITIVE SYNDROME; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RECOGNITION; SCHIZOPHRENIA; SENSORY STIMULATION; SIGNAL TRANSDUCTION; SOCIAL ATTITUDE; SOCIAL AVOIDANCE BEHAVIOR; STEREOTYPY; STRIATE CORTEX; TRANQUILIZING ACTIVITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; AVOIDANCE LEARNING; CATALEPSY; COGNITION; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOSTRIATUM; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PYRAZOLES; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR; STARTLE REACTION; STEREOTYPED BEHAVIOR;

EID: 70350445535     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.155994     Document Type: Article

References (50)

1. Brooks JM, Sarter M, and Bruno JP (2007) D2-like receptors in nucleus accumbens negatively modulate acetylcholine release in prefrontal cortex. Neuropharmacology 53:455-463. (Pubitemid 47212252)
2. Citri A and Malenka RC (2008) Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology 33:18-41. (Pubitemid 350191314)
3. Coskran TM, Morton D, Menniti FS, Adamowicz WO, Kleiman RJ, Ryan AM, Strick CA, Schmidt CJ, and Stephenson DT (2006) Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 54:1205-1213. (Pubitemid 44623341)
4. Crawley JN, Chen T, Puri A, Washburn R, Sullivan TL, Hill JM, Young NB, Nadler JJ, Moy SS, Young LJ, et al. (2007) Social approach behaviors in oxytocin knockout mice: comparison of two independent lines tested in different laboratory environments. Neuropeptides 41:145-163. (Pubitemid 46679054)
5. Elliott R, McKenna PJ, Robbins TW, and Sahakian BJ (1995) Neuropsychological evidence for frontostriatal dysfunction in schizophrenia. Psychol Med 25:619-630.
6. Graybiel AM (1990) Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 13:244-254.
7. Graybiel AM (2000) The basal ganglia. Curr Biol 10:R509-511.
8. Green MF, Kern RS, and Heaton RK (2004) Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 72:41-51.
9. Greengard P, Allen PB, and Nairn AC (1999) Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23:435-447. (Pubitemid 29359916)
10. Haber SN (2003) The primate basal ganglia: parallel and integrative networks. J Chem Neuroanat 26:317-330. (Pubitemid 38077155)
11. Harrison PJ (2004) The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology (Berl) 174:151-162.
12. Harvey PD, Green MF, Keefe RS, and Velligan DI (2004) Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry 65:361-372.
13. Harvey PD, Koren D, Reichenberg A, and Bowie CR (2006) Negative symptoms and cognitive deficits: what is the nature of their relationship? Schizophr Bull 32:250-258.
14. Haut MW, Cahill J, Cutlip WD, Stevenson JM, Makela EH, and Bloomfield SM (1996) On the nature of Wisconsin Card Sorting Test performance in schizophrenia. Psychiatry Res 65:15-22. (Pubitemid 26387209)
15. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
16. Hoffman DC and Donovan H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl) 120:128-133.
17. Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, and Kelly MP (2007) Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience 144:239-246. (Pubitemid 44839057)
18. Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, Meltzer HY, Green MF, Miller del D, Canive JM, et al. (2006) Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 31:2033-2046.
19. Kellendonk C, Simpson EH, Polan HJ, Malleret G, Vronskaya S, Winiger V, Moore H, and Kandel ER (2006) Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 49:603-615. (Pubitemid 43221894)
20. Kelly MP, Isiegas C, Cheung YF, Tokarczyk J, Yang X, Esposito MF, Rapoport DA, Fabian SA, Siegel SJ, Wand G, et al. (2007) Constitutive activation of Galphas within forebrain neurons causes deficits in sensorimotor gating because of PKA-dependent decreases in cAMP. Neuropsychopharmacology 32:577-588. (Pubitemid 46271052)
21. Kelly MP, Stein JM, Vecsey CG, Favilla C, Yang X, Bizily SF, Esposito MF, Wand G, Kanes SJ and Abel T (2008) Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia. Mol Psychiatry 14:398-415, 347.
22. Mäkinen J, Miettunen J, Isohanni M, and Koponen H (2008) Negative symptoms in schizophrenia: a review. Nord J Psychiatry 62:334-341.
23. Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR Jr., Nguyen HQ, Dawson LA, et al. (2007) WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7, 1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther 320:486-496.
24. Menniti FS, Chappie TA, Humphrey JM, and Schmidt CJ (2007) Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs 8:54-59. (Pubitemid 46438266)
25. Menniti FS, Faraci WS, and Schmidt CJ (2006) Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 5:660-670. (Pubitemid 44151604)
26. Moy SS, Nadler JJ, Perez A, Barbaro RP, Johns JM, Magnuson TR, Piven J, and Crawley JN (2004) Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain Behav 3:287-302. (Pubitemid 39277416)
27. Nishi A, Kuroiwa M, Miller DB, O'Callaghan JP, Bateup HS, Shuto T, Sotogaku N, Fukuda T, Heintz N, Greengard P, et al. (2008) Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 28:10460-10471.
28. Paglia MJ, Mou H, and Cote RH (2002) Regulation of photoreceptor phosphodiesterase (PDE6) by phosphorylation of its inhibitory gamma subunit re-evaluated. J Biol Chem 277:5017-5023. (Pubitemid 34968541)
29. Roche KW, O'Brien RJ, Mammen AL, Bernhardt J, and Huganir RL (1996) Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron 16:1179-1188. (Pubitemid 26227239)
30. Roche KW, Standley S, McCallum J, Dune Ly C, Ehlers MD, and Wenthold RJ (2001) Molecular determinants of NMDA receptor internalization. Nat Neurosci 4:794-802. (Pubitemid 32702511)
31. Rodefer JS, Murphy ER, and Baxter MG (2005) PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 21:1070-1076.
32. Rutten K, Prickaerts J, and Blokland A (2006) Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action. Neurobiol Learn Mem 85:132-138. (Pubitemid 43247839)
33. Sankoorikal GM, Kaercher KA, Boon CJ, Lee JK, and Brodkin ES (2006) A mouse model system for genetic analysis of sociability: C57BL/6J versus BALB/cJ inbred mouse strains. Biol Psychiatry 59:415-423.
34. Sano H, Nagai Y, Miyakawa T, Shigemoto R, and Yokoi M (2008) Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2. J Neurochem 105:546-556.
35. Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, et al. (2008) Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325:681-690. (Pubitemid 351574819)
36. Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, Lanfear J, Ryan AM, Schmidt CJ, Strick CA, et al. (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985:113-126. (Pubitemid 37088176)
37. Serulle Y, Zhang S, Ninan I, Puzzo D, McCarthy M, Khatri L, Arancio O, and Ziff EB (2007) A GluR1-cGKII interaction regulates AMPA receptor trafficking. Neuron 56:670-688. (Pubitemid 350102028)
38. Shepherd JD and Huganir RL (2007) The cell biology of synaptic plasticity: AMPA receptor trafficking. Annu Rev Cell Dev Biol 23:613-643.
39. Siuciak JA (2008) The role of phosphodiesterases in schizophrenia: therapeutic implications. CNS Drugs 22:983-993.
40. Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS, and Schmidt CJ (2006a) Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 51:386-396. (Pubitemid 44061894)
41. Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, Stock JL, McNeish JD, Strick CA, Menniti FS, et al. (2006b) Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology 51:374-385.
42. Spinetta MJ, Woodlee MT, Feinberg LM, Stroud C, Schallert K, Cormack LK, and Schallert T (2008) Alcohol-induced retrograde memory impairment in rats: prevention by caffeine. Psychopharmacology (Berl) 201:361-371.
43. Swerdlow NR and Geyer MA (1998) Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 24:285-301.
44. Tan HY, Callicott JH, and Weinberger DR (2007) Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb Cortex 17 (Suppl 1):i171-i181.
45. Threlfell S, Sammut S, Menniti FS, Schmidt CJ, and West AR (2009) Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to stimulation of frontal cortical afferents. J Pharmacol Exp Ther 328:785-795.
46. Wadenberg ML and Hicks PB (1999) The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 23:851-862.
47. Wadenberg ML, Kapur S, Soliman A, Jones C, and Vaccarino F (2000) Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 150:422-429. (Pubitemid 30470221)
48. Weber M, Breier M, Ko D, Thangaraj N, Marzan DE, and Swerdlow NR (2009) Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine. Psychopharmacology (Berl) 203:732-735.
49. Xie Z, Adamowicz WO, Eldred WD, Jakowski AB, Kleiman RJ, Morton DG, Stephenson DT, Strick CA, Williams RD, and Menniti FS (2006) Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience 139:597-607.
50. Young JW, Powell SB, Risbrough V, Marston HM, and Geyer MA (2009) Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 122:150-202.